NORCROSS, Ga., July 14, 2010 (GLOBE NEWSWIRE) -- Immucor, Inc. (Nasdaq:BLUD - News), a global leader in providing automated instrument-reagent systems to the blood transfusion industry, today announced CE (Conformite Europeenne) Mark approval for its Human Erythrocyte Antigen (HEA) BeadChip product for molecular immunohematology in vitro diagnostic purposes.
Through multiplex DNA analysis, Immucor’s HEA BeadChip product performs extended typing of 32 red blood cell antigens simultaneously. The CE Mark covers all antigens tested by the assay. The HEA BeadChip product allows blood banks to improve patient safety over current serology testing through the enhanced matching of patient and donor blood. “European regulatory clearance is a significant commercial milestone and validates the experience we’ve gained through more than 200,000 HEA tests. We view Europe as a key market to drive continued adoption of molecular methods in the blood bank,” stated Dr. Gioacchino De Chirico, Immucor’s President and Chief Executive Officer. “We believe the DNA testing of blood prior to transfusion will improve patient safety and transform transfusion medicine.”
Immucor has already received CE Mark approval for its Human Platelet Antigen (HPA) assay for use in platelet genotyping and its instrument, the Array Imaging System and BASIS(TM) database, which facilitates the reading and interpretation of molecular test results.
Immucor’s BioArray Solutions product line is a leader in setting the standard for molecular immunohematology. The HEA BeadChip product is Immucor’s core assay for extended typing of red blood cell antigens from a DNA sample. The HEA BeadChip product predicts the phenotypes of the Rh (C,c,E,e), Kell (K, k, Kpa, Kpb, Jsa, Jsb), Duffy, Kidd, MNS, Lutheran, Dombrock (Doa, Dob, Hy, Jo), Landsteiner-Wiener, Diego, Colton, and Scianna blood group systems. Learn more at www.immucor.com/bioarray.
About Immucor
Founded in 1982, Immucor manufactures and sells a complete line of reagents and systems used by hospitals, reference laboratories and donor centers to detect and identify certain properties of the cell and serum components of blood prior to transfusion. Immucor markets a complete family of automated instrumentation for all of its market segments. For more information on Immucor, please visit our website at www.immucor.com.
Statements contained in this press release that are not statements of historical fact are “forward-looking statements” as that term is defined under federal securities laws, including, without limitation, all statements concerning Immucor’s expectations, beliefs, intentions or strategies for the future. Forward-looking statements may be identified by words such as “plans,” “expects,” “believes,” “anticipates,” “estimates,” “projects,” “may,” “will,” “could”, “should” and other words of similar meaning. Investors are cautioned not to place undue reliance on any forward-looking statements, and Immucor assumes no obligation to update any forward-looking statements. Immucor urges investors to consider the risks detailed in the Company’s filings with the Securities and Exchange Commission.
